NNZ-2591

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameNNZ-2591
Drug Alias NameCyclo-L-Glycyl-L-2-AllylprolineCycloG-2-allyl-PcG-2-Allyl-PNNZ-2591ACP-2591 +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionNeuropeptide receptor modulatorsSymporters modulatorsSynaptic transmission modulators +[4] 
TargetsNeuropeptide receptorSymporters
Therapy Area/IndicationsPhelan-McDermid syndromePitt-Hopkins syndromePrader-Willi Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeuren Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeuren Pharmaceuticals LtdAcadia Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsPhelan-McDermid syndromePitt-Hopkins syndromeAngelman Syndrome
Inactive IndicationsPrader-Willi Syndrome

Other Information

ATC CodeN/A
Related LinksN/A